worldwide offices | stay connected | contact | help | sitemap
Home
Products
Products home
Pharmaceuticals
Vaccines and Diagnostics
Sandoz (Generics)
Over-the-Counter
Animal Health
CIBA Vision
Diseases & Conditions
Diseases & Conditions home
Dengue
Tuberculosis
Malaria
R&D
R&D home
Drug discovery and development process
Novartis Institutes for BioMedical Research (NIBR)
Pharmaceutical Development
Novartis Biologics
Corporate Research
Research and Development locations
About Novartis
About Novartis home
Mission
Businesses
People
Corporate citizenship
Partnerships
Locations
Company history
Investors
Investors home
Sales and results
Share data and analysis
Fixed-income securities
Presentations and events
Shareholders' corner
Corporate governance
Investor relations contacts
Newsroom
Newsroom home
Media releases
Influenza A(H1N1) information center
FTY720 FREEDOMS data
Feature stories
Fact sheet
Novartis corporate press kit
Media library
Corporate publications
Novartis newsrooms
Media contacts
Careers
Careers home
Culture and values
Career development
Compensation and benefits
Diversity and inclusion
Corporate Volunteerism
Graduate students - BioCamp
Careers in research
Employee profiles
Job search
Job search - US
stay connected
contact
help
sitemap
terms of use
privacy policy
Find out about upcoming events for shareholders, and view archived presentations and webcasts from past events.
‹ previous
next ›
Month
Event
SWX
NYSE
NOVZn
See stock performance
NVS
Download our latest financial reports.
Annual Report 2008
Form 20-F(1.1 MB)
Visit our order and download center
08-Oct-2009Novartis gains exclusive worldwide rights to PTK 0796, in Phase III study as potential first-in-class IV and oral broad-spectrum antibiotic
Visit our newsroom
Use of this website is governed by our Terms of use and Privacy policy. © Novartis AG